Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity - Wikidata - wikimedia - TriplyDB

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

http://www.wikidata.org/entity/Q34617633

about

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling.Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.Targeting plasma cells: are we any closer to a panacea for diseases of antibody-secreting cells?Cereblon in health and disease.Modulation of cereblon levels by anti-myeloma agents.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma.Understanding the multiple biological aspects leading to myeloma Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a Cereblon-independent manner.Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.Zeroing in on cereblon.Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients.Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome

P2860

Q30802505-B3D8F826-2C0F-40DC-BBD6-217AA4281553 Q33556826-1C2F9A95-9285-4C50-A700-7B9DF0C926FB Q33846806-8FBFC99C-085C-411C-B138-2844B9C3CC7A Q35784505-FC466865-1E9C-4B6A-B262-E3D5C575CA7E Q35796527-CD0C8351-ACD1-4AEB-BB5C-D0FBCA20B167 Q36299827-C8215215-F1E6-4A8E-BA3E-095D0768C6B5 Q37409668-C3AF11F9-0F5E-4CFE-9FC3-4D26211DCE82 Q38462720-838ED80B-AAE4-41AD-9BC4-5D5FED9BDC3C Q38612199-85287D23-D894-4624-8C87-FBEE4154249C Q38656507-A92C6AC3-CD61-4414-889F-B581801A479C Q38724074-72EA4AE7-8671-4093-A37C-CB3B3D680945 Q38728585-C1D8CEE2-0189-4F7E-BC3F-81B334EA54A5 Q38876495-F7CD09AC-A0B0-4DB2-95E4-88DC8339D0DC Q38888980-DE5762E4-EC47-4017-AA04-21CF432847D4 Q38968027-325C14DD-F317-41FF-9809-7DB6BD0F3E7A Q39040840-1DAEE684-D605-48F7-AC1F-7F27834F8E5A Q39065368-FEA7E0CB-41B7-429D-A4E8-188C9B9EFB89 Q41138910-DB72C005-C128-4E12-B3D7-9886FC1C8584 Q41660363-2D7A6F24-F760-40E8-895F-CE24FE480AE2 Q42385107-88E4743F-34AC-4C91-913D-EF4739398650 Q42563529-E501EC72-945A-4E07-8F8D-FB8ADC46FAE6 Q42696060-6331884B-26F2-4B15-B5EB-47030FB30844 Q43104067-8D144513-F7AF-46CB-80F8-FA1BE4201EB1 Q46275503-0744C197-0A6B-4C01-8095-66A83BC2AF00 Q49960388-6E2980FB-FE7F-4EF7-B7E9-31B79F4DAA04 Q50864223-5F5697EF-0D06-42E2-8DC5-F4FF1ACD358D Q52653307-C611F27F-5B6E-4353-BF6F-6E82FEAB2C6B Q53581670-85B9EC5D-2532-49F4-85C6-7C5617F5757E Q53687540-BE26512D-E469-41B2-809A-2AD69B459AE8 Q54204985-A66F2941-4E64-4AEF-9871-53E5665AF327 Q54977029-D12D9C3B-70AB-404B-99F9-2BCCE92809B0 Q56866834-89697732-B178-4CBF-8CBD-2A1DB13D4A41

P2860

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

http://www.wikidata.org/entity/Q34617633

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Measuring cereblon as a biomar ...... derstanding of gene complexity

@ast

Measuring cereblon as a biomar ...... derstanding of gene complexity

@en

Measuring cereblon as a biomar ...... derstanding of gene complexity

@nl

type

label

Measuring cereblon as a biomar ...... derstanding of gene complexity

@ast

Measuring cereblon as a biomar ...... derstanding of gene complexity

@en

Measuring cereblon as a biomar ...... derstanding of gene complexity

@nl

prefLabel

Measuring cereblon as a biomar ...... derstanding of gene complexity

@ast

Measuring cereblon as a biomar ...... derstanding of gene complexity

@en

Measuring cereblon as a biomar ...... derstanding of gene complexity

@nl

P1433

Q34617633-0D1E0D62-5948-479D-BA70-65A17A52514D

P1476

Q34617633-8CE418D7-5D52-40D4-9F16-BEB2FCEA8F6A

P2093

Q34617633-0C2D7271-EF24-447E-AC4E-A454D3B024E6

Q34617633-1D86B60B-C2C8-4100-BE95-CF6E90309A07

Q34617633-331EA7E7-3BB7-4769-875C-3C841CF621EC

Q34617633-469856FD-D6A5-4101-96CA-AEED32FAD4CD

Q34617633-4C3A4FFE-F2A6-4C31-9656-93885A7B02C4

Q34617633-55780A8C-D283-4DBB-BA09-762AA2E2DD55

Q34617633-6849F797-5708-442B-BC02-19A708A5C285

Q34617633-6C7EC40A-90CC-48C6-8F13-E4AB18FDB6A5

Q34617633-72FF6957-C145-4770-B49B-CC32CF8EB5DD

Q34617633-779A169C-6568-455B-ABEE-BBC68FD4FA59

P2860

Q34617633-009166B9-EDBA-4595-B292-03211DFA94D3

Q34617633-03AF5295-5B99-4F82-8523-DA8BA9423EF9

Q34617633-1EDA1969-35E6-48BC-A478-2402E7E9D7FE

Q34617633-2AEF8F6C-9DA1-4B41-8AE9-337A61D5CA11

Q34617633-3A67F85F-1AC4-4472-BF37-258C781597FD

Q34617633-52AB2AF4-7F2C-4DCD-9E0D-84102BF6D0EA

Q34617633-614413CA-1D02-4330-8223-2BF10B244044

Q34617633-686C2872-42DF-4FBC-9F70-3B47CE240E49

Q34617633-756D3A53-0A5A-4707-BFC2-D2D0A76BA247

Q34617633-8B71C276-6341-4E06-9A0A-6649E2930994

P304

Q34617633-0E4A13A4-A245-4FBF-B180-8B5DB9D6D529

P31

Q34617633-C2B4D5E4-7283-45EF-A27D-8B570C142D0E

P356

Q34617633-7336D608-60B9-48A3-97BD-7DBD82B3CEEA

P407

Q34617633-A5D67BFB-56B0-4F55-AE2B-9D4B702F7D58

P433

Q34617633-79D301F3-05D1-4082-BB82-4E93CEA36ED6

P478

Q34617633-B1DA30D4-BBFA-4BFA-B73E-B14CA807F28B

P577

Q34617633-338D2548-E99A-4C98-BA2E-1CC5FF7B2143

P5875

Q34617633-E2C79F3C-58DA-483A-8F09-1F54FDB73A9C

P698

Q34617633-9069978E-CCE1-4235-8B04-52ADE04F3BD9

P921

Q34617633-00C5EB34-513B-4522-BCBB-F3E28EB453D5

P932

Q34617633-98DF13FB-E888-461D-800A-AAB20764479D

P356

P1433

British Journal of Haematology

P1476

Measuring cereblon as a biomar ...... derstanding of gene complexity

@en

P2093

Afshin Mahmoudi

http://www.w3.org/2001/XMLSchema#string

Anita K Gandhi

http://www.w3.org/2001/XMLSchema#string

Anjan Thakurta

http://www.w3.org/2001/XMLSchema#string

Antonia Lopez-Girona

http://www.w3.org/2001/XMLSchema#string

Brian E Cathers

http://www.w3.org/2001/XMLSchema#string

Derek Mendy

http://www.w3.org/2001/XMLSchema#string

Emily Rychak

http://www.w3.org/2001/XMLSchema#string

Gengxin Chen

http://www.w3.org/2001/XMLSchema#string

Gilles Carmel

http://www.w3.org/2001/XMLSchema#string

Karen Miller

http://www.w3.org/2001/XMLSchema#string

P2860

The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage

Identification of a primary target of thalidomide teratogenicity

Genome-wide association study of antibody response to smallpox vaccine

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Initial genome sequencing and analysis of multiple myeloma

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance

Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

Frequent pathway mutations of splicing machinery in myelodysplasia

P304

233-244

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12622

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

164

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258425301

http://www.w3.org/2001/XMLSchema#string

P698

24206017

http://www.w3.org/2001/XMLSchema#string

P921

P932

4253085

http://www.w3.org/2001/XMLSchema#string